Biotalys NV (BTLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biotalys NV (BTLS) has a cash flow conversion efficiency ratio of -0.154x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.05 Million ≈ $-3.56 Million USD) by net assets (€19.81 Million ≈ $23.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biotalys NV - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Biotalys NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Biotalys NV for a breakdown of total debt and financial obligations.
Biotalys NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biotalys NV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MICROPORT CARDIO.MEDTECH.
F:72X
|
N/A |
|
LIG-ES SPAC
KQ:220260
|
0.025x |
|
Samyang Tongsang Co. Ltd.
KO:002170
|
0.026x |
|
W5 Solutions AB
ST:W5
|
0.082x |
|
Loop Telecommunication International Inc
TW:3025
|
-0.014x |
|
Hotron Precision Electronic Industrial Co Ltd
TW:3092
|
-0.048x |
|
Donegal Group B Inc
NASDAQ:DGICB
|
0.016x |
|
Uniquest
KO:077500
|
-0.059x |
Annual Cash Flow Conversion Efficiency for Biotalys NV (2019–2024)
The table below shows the annual cash flow conversion efficiency of Biotalys NV from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Biotalys NV stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €27.61 Million ≈ $32.27 Million |
€-12.65 Million ≈ $-14.79 Million |
-0.458x | +35.91% |
| 2023-12-31 | €25.57 Million ≈ $29.89 Million |
€-18.28 Million ≈ $-21.37 Million |
-0.715x | -35.65% |
| 2022-12-31 | €38.11 Million ≈ $44.56 Million |
€-20.09 Million ≈ $-23.49 Million |
-0.527x | -85.36% |
| 2021-12-31 | €58.91 Million ≈ $68.88 Million |
€-16.75 Million ≈ $-19.59 Million |
-0.284x | +23.49% |
| 2020-12-31 | €25.65 Million ≈ $29.99 Million |
€-9.53 Million ≈ $-11.15 Million |
-0.372x | +4.76% |
| 2019-12-31 | €21.07 Million ≈ $24.64 Million |
€-8.22 Million ≈ $-9.61 Million |
-0.390x | -- |
About Biotalys NV
Biotalys NV, an agricultural technology company, discovers and develops protein-based biocontrol solutions in Belgium and internationally. The company offers biofungicides and bioinsecticides. It also provides the AGROBODY Foundry technology platform, which generates protein-based crop protection products. In addition, the company develops EVOCA 1st generation, EVOCA Next generation, and BIOFUN-6… Read more